INTRODUCTION
Diabetes mellitus (DM) is a group of metabolic disorders with multiple etiologies characterized by impaired metabolism of carbohydrates, proteins, and fat that is caused by complete or relative insuffi ciency of insulin secretion and/or action of insulin. [1] It has been established that diabetes during pregnancy leads to reproductive abnormalities in the offspring such as altered fetal growth, polyhydramnios, congenital defects, and spontaneous abortion. [2] [3] [4] [5] [6] Infants born to diabetic mother are shown to have hypocalcemia and lower bone mineral content at birth. [4, [7] [8] [9] In addition, hypoplasia of neurocranial, viscerocranial, forelimb, and hindlimb bones have been observed in the fetuses of streptozotocin (STZ)-induced diabetic pregnant rats. [10] The mechanism of ossifi cation defects in the offspring of diabetic rats have been explained by two models: [11] The push model suggests insuffi cient supply of Ca 2+  to the fetus due to excessive Ca 2+ loss in maternal urine [12] or due to decreased capacity of the placenta to transport Ca 2+ , [13] while the pull model explains that the demand for Ca 2+ is reduced in the fetus due to defects in the process of bone maturation itself, as indicated by reduced cord osteocalcin levels [14] and a decreased number of ossifi cation centers. However, Verhaeghe et al. support the latter model. [15] The plant Cissus quadrangularis (CQ) (Veldt Grape or Winged tree-bine), a climber belonging to the family Vitaceae, has been used as an osteogenic/osteoprotective medicine in Ayurveda. In India, CQ is one of the widely used medicinal plants. [16] This plant grows in the hotter regions of India, Sri Lanka, Malaysia, Java and West Africa. [17] This plant can heal broken bones and thus is commonly known as "bone setter," or Asthisandhani in Sanskrit and Hadjod in Hindi. [18] Phytochemical studies of CQ have reported the presence of several compounds such as ascorbic acid, carotene, calcium, anabolic steroidal substances, -sitosterol, -amyrin, -amyrone, flavonoids, triterpinoids, [19] [20] [21] [22] quercetin, resveratrol, piceatannol, pallidol perthenocissin, and phytosterols. [23] [24] [25] [26] Pharmacological studies have demonstrated that unidentifi ed anabolic steroid acts on the estrogen receptors of bone cells and facilitates healing of fractured bones. [27] In vitro studies have suggested that phytoestrogens, estrogenic compounds derived from plants, seem to have actions similar to that of estrogen on bone cells. [28, 29] The role of receptor-mediated action of estrogen on osteoblasts and osteoclasts has been studied previously. [30] [31] [32] Furthermore, the stimulatory effect of 17-beta estradiol on the process of bone matrix formation and mineralization in hyperglycemic conditions has been reported. [33, 34] Alterations in the environmental factors during early development have been shown to permanently program the structure and physiology of the body's tissues and system. [35] It has been proved that excessive estrogen exposure can result in altered programming of the bone cells, and the same has been shown to have long-lasting effects on fetal skeleton. [36] Plant-derived estrogen mimicking the phytoestrogens are shown to cross the placenta in humans. [37, 38] In past, the benefi cial effects of antioxidants and medicinal plants that affect the antioxidant status during pregnancy have been studied on diabetes-induced fetal ossifi cation defects. [11, 39] However, the role of phytoestrogens on fetal skeletal ossifi cation in diabetic rats has not been studied.
Earlier studies have shown that prenatal exposure of petroleum ether extract of CQ (PECQ) stimulates fetal skeletal growth. [40, 41] We observed that the prenatal exposure of PECQ can signifi cantly improve bone mass in the offspring at their adult age (unpublished data). Therefore, the present study was designed to investigate the protective effect of PECQ on diabetes-induced delayed fetal skeletal ossifi cation.
MATERIALS AND METHODS

Plant material and preparation of extract
Fresh stems of CQ plant were collected in Belgaum, Karnataka, India. The plant was identified and authenticated with the help of a taxonomist. The fl eshy stems were washed and air-dried, and then the dried stems were grinded into powder. The powder (1.3 kg) was then thoroughly extracted with 95% ethanol in a soxhlet apparatus, and the yield was concentrated under reduced pressure. Next, the total yield of ethanol extract (125 g) was suspended in water and partitioned with petroleum ether to obtain PECQ with a yield of 11.4 g (9.1% w/w). PECQ was stored in air-and water-proof containers and kept in refrigerators at 4°C. During the experiment, PECQ was diluted in 0.5% carboxy methyl cellulose (CMC) before administration to animals. 
Animals
Experimental design
Female rats were rendered diabetic by a single intraperitonial injection of STZ (Sigma Chemical, St. Louis, MO, USA) at a dose of 40 mg/kg body weight dissolved in citrate buffer, 7 days before the mating period described earlier. [39] Normal control rats were injected with citrate buffer only. Animals demonstrating hyperglycemia (270 mg/dl) within 36 hour of injection were included in the study. After confi rmation of the onset of diabetes, the diabetic female rats were allowed to mate with non-diabetic male rats, and non-diabetic female rats were mated with non-diabetic male rats. After confi rmation of pregnancy, the pregnant rats were divided into three groups (n6), The normal control group, diabetic control group, and diabeticCQ group. Both the normal and diabetic control groups received equivalent volume of 0.5% CMC orally throughout the gestation period. The diabetic CQ group rats were treated orally with PECQ at a dose of 500 mg/kg body weight/day in 0.5% CMC throughout the gestation. The dose of PECQ was fi xed based on the previous acute toxicity studies, where administration of PECQ extract up to 5000 mg/kg body weight did not show any adverse effects. [41] Blood glucose level and body weight were measured at intervals of 0, 5, 14, and 21 days of pregnancy. Blood glucose levels were measured using accu-chek active glucose strips (Roche Diagnostic India Pvt. Ltd, Mumbai).
Alizarin red S-alcian blue preparation
At the end of the gestation, immediately after delivery, pups were collected from all experimental groups. Under anesthesia, the skin, viscera, and adipose tissues were carefully removed from the neonatal pups. Then the eviscerated pups were processed for alizarin red S-alcian blue (Sigma Chemical, USA) double staining to view the ossifi ed and unossifi ed skeleton. [42] Ossifi cation centers in the sternum, metacarpus, metatarsus, phalanges, and caudal vertebrae (n18 pups in each experimental group) were recorded with the aid of a stereomicroscope.
Morphometric analysis of limbs
Photographs of the double-stained limbs were taken with fi xed scales to measure the length of ossifi ed skeleton and that of the total length of the bones using Image J software. Length of the scapula, humerus, ulna, radius, femur, tibia, and fi bula were measured (n12 limbs in each experimental group), and the percentages of the total length of the mineralized skeletons in the normal control, diabetic control, and diabeticCQ treated groups were calculated as previously described. [41] 
Statistical analysis
Results were expressed as meanstandard errors of mean. The data was analyzed using Graph pad Prism software (Microsoft, San Diego, CA, USA). Repeated measures ANOVA followed by Bonferroni's multiple comparison test was employed to compare the data for maternal glycemia and body weight. Ossifi cation centers and the total length of the bone precursor cartilages were analyzed by applying one-way ANOVA followed by the Bonferroni's multiple comparison test to determine the specifi c difference between the groups. P 0.05 was considered to indicate statistical signifi cance.
RESULTS
Effect of petroleum ether extract of cissus quadrangularis (PECQ) on glycemia during pregnancy
Blood glucose level was measured on days 0, 5, 14, and 21 of pregnancy. In normal control rats, normoglycemia was confi rmed with mean glucose value119 mg/dl. In the diabetic control rats, a signifi cant hyperglycemia (P0.05) was noted during pregnancy as compared to that in the normal control rats. Furthermore, no alteration in the blood glucose level was observed when diabetic pregnant rats were treated with PECQ [ Table 1 ]. This result indicates that the PECQ administration does not directly interfere with the blood glucose level.
Effect of PECQ on maternal weight gain during pregnancy
Throughout pregnancy, an increase in the body weight was observed in the normal control rats. On the other hand, the diabetic control rats showed signifi cantly (P0.05) lower body weight on days 0, 5, 14, and 21 of pregnancy as compared to the normal control group. However, PECQ administration to diabetic pregnant mother signifi cantly (P0.05) improved the body weight gain on 0, 5, 14, and 21 days of pregnancy [ Table 2 ].
Effect of PECQ on ossifi cation centers
Pups born to the diabetic control group rats showed signifi cantly less ossifi cation centers at the time of birth when compared to the pups of the normal control group (sternum, metacarpus, anterior phalanges, posterior phalanges, and caudal vertebrae; P0.001 and metatarsus; P0.01). Interestingly, pups born to the diabetic mother treated with PECQ showed signifi cantly increased number of ossifi cation centers in the bones at birth (sternum, metacarpus, posterior phalanges, and caudal vertebrae: P 0.001; anterior phalanges: P 0.01; metatarsus: P 0.05) when compared to the pups of the diabetic control group [ Table 3 and Figures 1-3] . Therefore, PECQ can infl uence the fetal ossifi cation process and can prevent diabetes-induced delay in the onset of the ossifi cation during fetal life.
Effect of PECQ on the ossifi cation of forelimb and hindlimb bones Morphometric analysis
The Image J data revealed signifi cant differences in the extent of ossifi cation of forelimb and hindlimb bones at birth of pups in the diabetic control group as compared to those in the normal control group. However, pups born to PECQ-treated diabetic mother showed signifi cant improvement in the extent of ossifi cation in the limb bones. 
Effect of PECQ on the ossifi cation of forelimb bones
The mean length of the ossifi ed scapula and humerus in the pups born to the normal control group were 3.550.03 mm (70.71.08% of the total length of the scapula) and 3.730.05 mm (64.191.09% of the total length of the humerus), respectively. However, the mean length of the ossifi ed scapula and humerus in the pups born to the diabetic control group were signifi cantly decreased (scapula: 2.410.04 mm, 56.010.74% of the total length (P0.001); humerus: 2.320.03 mm, 46 The mean length of the ossifi ed ulna and radius in the pups born to normal control group were 4.230.01 mm (73.82  0.95% of the total length of the ulna) and 3.390.02 mm (69.530.72% of the total length of the radius) respectively. However, the mean length of ossifi ed ulna and radius in the pups of diabetic control mothers were found to be signifi cantly decreased to about 15% as Figures 4 and 5) .
Effect of PECQ on the ossifi cation of hindlimb bones
The mean length of the ossifi ed femur in the pups of the normal control mothers was 3.030.05 mm (n12; 54.9 0.78% of the total length of the femur), while the mean length of the ossifi ed femur in the pups of the diabetic control mothers was signifi cantly (P0.001) lower as compared to that in the pups of normal control mothers (femur: 2.040.05 mm, 44.311.11% of the total length, Figures 6 and 7) . However, diabetes-induced delayed fetal ossifi cation in the femur was brought back to near normal in the pups of PECQ-treated mothers (2.710.08 mm, 50.571.16% of the total length, Figures 6 and 7) .
The mean length of the ossifi ed tibia and fi bula in the pups of normal control mothers were 3.77  0.04 mm (65.49  0.95% of the total length of the tibia) and 3.59  0.05 mm (67.81  0.67% of the total length of the fi bula), respectively. However, the ossifi ed portion of these bones signifi cantly (P0.001) decreased in the pups of diabetic control mothers (tibia: 2.430.04 mm, 51.361.07% of the total length; fi bula: 2.310.03 mm, 51.6  1.03% of the total length, Figures 6 and 7) . Similar to the upper limb bones, the mean length of the ossifi ed tibia and fi bula were found to be signifi cantly increased in the pups of PECQ-treated diabetic mothers as compared to the pups of diabetic control mothers (tibia: 3.450.03 mm, 61.131.15% of the total length (P0.001); fi bula: 3.440.04 mm, 63.340.87% of the total length (P0.001), Figures 6 and 7) .
DISCUSSION
DM in pregnancy can be divided into clinical diabetes and gestational diabetes. [43] In the present study, we produced animal model for clinical diabetes with STZ administration (40 mg/kg) to rats during their adult life using the venous route, before pregnancy. This model mimics women with uncontrolled clinical diabetes during pregnancy. Diabetic rats had blood glucose levels 270 mg/dl and showed reduced body weight during pregnancy. The reduced body weight may be due to the metabolic alterations caused by hyperglycemia/hypoinsulinemia. [39] These findings are similar to those reported in previously performed Figure 5 : Alizarin red S-alcian blue stained forelimb bones showing ossified and unossified portions in neonatal pups born to the experimental groups at term pregnancy. The length of the ossifi ed portion of the forelimb bones in the neonatal pups of D group was found to be lesser than that of C group. However, the length of the ossifi ed portion of these bones was increased with PECQ treatment. Scale bar1 cm Figure 6 : Percentages of the total length of ossifi ed portion of hindlimb bones in the neonatal pups of the experimental groups. Pups of the D group showed signifi cant decrease in the length of the ossifi ed portion of hindlimb bones in comparison to that of the C group. However, when diabetic pregnant rats were treated with PECQ, the ossifi ed portions of these bones were brought back near to normal. Data presented as means SEM. Signifi cant differences versus D group are indicated as ***P0.00 Figure 7 : Alizarin red S-alcian blue stained hindlimb bones showing ossifi ed and unossifi ed portions in the neonatal pups of the experimental groups at term pregnancy. The proportionate length of the ossifi ed portion of the hindlimb bones was found to be decreased in the neonatal pups of the D group than that of the C group. However, the length of the ossifi ed portion of these bones was increased with PECQ treatment. Scale bar1 cm studies. [39, 44, 45] Interestingly, the gain of maternal body weight during pregnancy was improved with the PECQ treatment when compared to the diabetic group. As PECQ did not interfere in the glycemic condition of the diabetic rats, the positive effect of PECQ on maternal body weight may be attributed to its antioxidant property. [46] The morphometric analysis of limb bones and decreased number of onset of ossifi cation centers in the current study revealed infl uence of maternal diabetes on fetal skeletal ossifi cation in the offspring of diabetic rats. Similar results were reported earlier in studies of the effect of hyperglycemia during pregnancy on fetal skeletal ossifi cation. [10, 11] In the past, it has been shown that treating animals with PECQ from 9 th to 21 st day of gestation affects the fetal skeletal ossifi cation and improves the cortical and trabecular bone mass in the offspring. [40, 41] In the present study, the offspring of diabetic rats treated with PECQ throughout the gestation have shown increased number of ossification centers and improved percentages of the total length of ossifi ed cartilage of limb bones as compared to that in the diabetic group. These results indicate that PECQ has the potential to normalize defective skeletal development in the offspring of diabetic rats. Present morphometric analysis of limb bones, for the fi rst time, revealed that maternal exposure of PECQ to diabetic rats can effectively prevent delayed skeletal ossifi cation in fetal limb bones.
Enhancing effect of PECQ on fetal osteogenesis observed in the present study could be attributed to phytogenic, steroid-like compounds present in it that probably act as phytoestrogens and effectively cross the placental barrier to affect the fetal skeletal growth. [27] Presence of several phytosteroids in the CQ extract has been studied. [19] It also been shown that such phytoestrogens can pass through the placental barrier. [37, 38] The pharmacological effect of PECQ on fetal skeletal ossifi cation can also be explained by the study conducted by Migliaccio et al., where altered maternal estrogen levels during the pregnancy resulted in long-lasting changes in the skeletons of neonatal pups, suggesting the stimulatory effect of prenatal exposure of estrogen on fetal skeletal growth. [36] Reports suggest that ossifi cation defects in the offspring of diabetic rats are due to the defi cient bone maturation during the embryonic period. [15] An in vitro study showed that PECQ can enhance the mesenchymal stem cell proliferation and facilitate osteoblastogenesis. [47] In addition, it has been shown that estrogen stimulates proliferation and differentiation of osteoblasts. [48, 49] Therefore, the effects of PECQ observed in the present study may be due to the phytogenic steroids present in it, which may have acted as an analog of estrogen and enhanced the proliferation and differentiation of the osteoblasts and facilitated the mineralization process in the hyperglycemic conditions. Furthermore, Gopalakrishnan et al. reported that the synthetic estrogen facilitates mineralization in the presence of high glucose in vitro [34] and that treatment with estrogen can reverse diabetes-induced osteopenic changes in adult rats. [33] Thus, the stimulatory effect of PECQ on defective fetal ossifi cation in maternal diabetes may be due to estrogen-mimicking action of phytosteroids present in PECQ, which may promote fetal bone maturation in diabetic state.
Intra-uterine environment plays an important role in programming the risk of developing chronic diseases such as cardiovascular disease, diabetes, and osteoporosis later in life. [35] Poor intrauterine bone growth may program an increased susceptibility and risk for developing osteoporosis later in life. [50] Therefore, defective/delayed fetal skeletal development in maternal diabetes may lead to osteoporosis in their offspring later in life. In such cases, PECQ treatment may be useful to normalize the maternal diabetes-induced delay in fetal skeletal ossifi cation and to protect offspring from osteoporosis later in life.
Furthermore, it has been shown that the CQ extract can act as a free radical scavenger, [51] and ROS has been proposed for pathogenesis diabetes-induced malformations. [52] In addition, decreased rate of malformations were observed in the offspring of diabetic rats fed with inositol, arachidonic acid, and antioxidants. [53] [54] [55] [56] [57] Therefore, reduced skeletal malformations in the offspring of PECQ-treated diabetic mother may be due to its antioxidant properties as well. However, the antioxidant role of PECQ extract in diabetic rat model needs further evaluation.
CONCLUSION
Our results provide evidence that PECQ treatment can effectively ameliorate the defective skeletal development in the offspring of diabetic rats. This may be due to the antioxidant as well as pro-osteogenic properties of PECQ. Further studies on isolation and characterization of the active chemical constituents of PECQ that can cross the placental barrier and that are responsible for bone anabolic activity are warranted.
